support@mellalta.com   +1 (304) 306-0723

How selinexor (Xpovio) is positioned in competitive R/R DLBCL market?

SELINEXOR-XPOVIO-COMPETITIVE-POSITIONING-IN-DLBCL

Karyopharm’s Selinexor (Xpovio)  an oral selective inhibitor of nuclear export (SINE) compound inhibiting the nuclear export protein exportin 1 (XPO1) was granted accelerated approval for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma. The drug is also approved a year ago as the “last line” treatment option for relapsed/refractory Multiple Myeloma patients.

Key Takeaways by Mellalta Meets

Karopharm DLBCL selinexor

Selinexor (Xpovio) Marketing Positioning Statements

  • First oral therapy approved for RR DLBCL
  • First single agent approved in any line of DLBCL treatment
  • First therapy a RR DLBCL patient can take at home

Selinexor (Xpovio) Market Positioning

  • Selinexor (Xpovio) will be preferred as a DLBCL treatment option after two prior lines of therapy
  • An Estimated 9,000 DLBCL Patients Being Treated in the 3rd and 4th Line+ Setting in the U.S.
  • Recent FDA approvals of CAR-T therapy (2017 and 2019) and polatuzumab + bendamustine + rituximab (2019)

Market Positioning XPOVIO (selinexor)

The approval of Karyopharm’s Xpovio (selinexor) in patients with relapsed or refractory DLBCL is a huge milestone for the patients and families suffering as they have limited treatment options available for their disease.

Submit your Request for Proposals at bd@mellalta.com

You might be interested in …

Leave a Reply

Get In Touch

Let's keep the conversation going